Holen Sie sich die Stockscreener-App
6.43
0.94%
0.06
Handel nachbörslich:
6.43
Nuvectis Pharma Inc Aktie (NVCT) Neueste Nachrichten
Roth Capital Expects Stronger Earnings for Nuvectis Pharma - Defense World
Real time scanner hits for Nuvectis Pharma Inc. explainedEarnings Growth Report & Stepwise Swing Trade Plans - Newser
Is Nuvectis Pharma Inc. trending in predictive chart modelsJuly 2025 Reactions & Capital Efficient Trading Techniques - Newser
Is Nuvectis Pharma Inc. building a consolidation base2025 Dividend Review & Daily Chart Pattern Signal Reports - Newser
What indicators show strength in Nuvectis Pharma Inc.Earnings Beat & Reliable Price Breakout Signals - Newser
Evaluating Nuvectis Pharma Inc. with trendline analysisGDP Growth & Verified High Yield Trade Plans - Newser
Using R and stats models for Nuvectis Pharma Inc. forecastingPortfolio Risk Report & Entry Point Confirmation Alerts - Newser
Is it time to cut losses on Nuvectis Pharma Inc.Fed Meeting & Daily Oversold Bounce Ideas - Newser
what makes nuvectis pharma inc. stock price move sharplyFree Buy Signal Based on Chart Analysis - Newser
Does Nuvectis Pharma Inc. fit your quant trading model2025 Analyst Calls & Detailed Earnings Play Strategies - Newser
Developing predictive dashboards with Nuvectis Pharma Inc. dataFree Price Action Based Buy Opportunity List - Newser
What makes Nuvectis Pharma Inc. stock price move sharplyWeekly Breakout Forecast with Entry Zones - Newser
Why Nuvectis Pharma Inc. stock attracts strong analyst attentionFree Community Verified Stock Suggestions - Newser
Nuvectis initiates phase 1b program for cancer drug NXP900 - Investing.com
Nuvectis Pharma Announces the Initiation of the Phase 1b Program for NXP900 - GlobeNewswire
Nuvectis Expands Cancer Drug Trial to Target Multiple Resistant Tumors with Precision Medicine - Stock Titan
Key resistance and support levels for Nuvectis Pharma Inc.Volume Spike Detection for Early Breakouts - Newser
How to track smart money flows in Nuvectis Pharma Inc.Strategy Builder for Growth Focused Traders - Newser
Volume spikes in Nuvectis Pharma Inc. stock – what they meanFree Pattern Detection for Entry Confirmation - Newser
Nuvectis Pharma (NASDAQ:NVCT) Is In A Good Position To Deliver On Growth Plans - 富途牛牛
Nuvectis Pharma, Inc.'s (NASDAQ:NVCT) stock price dropped 12% last week; retail investors would not be happy - simplywall.st
RSI Suggests Rebound May Be Near in Nuvectis Pharma Inc.Breakout Confirmation With Entry Tracker Enabled - beatles.ru
Will Nuvectis Pharma Inc. stock recover after recent dropReal Time Trade Execution Alert Plan - Newser
How to forecast Nuvectis Pharma Inc. trends using time seriesWatchlist Generator for Smart Money Signals - Newser
Nuvectis Pharma cuts NXP800 in ovarian cancer after early failure - MSN
Nuvectis Pharma Inc. stock daily chart insightsSwing Watchlist With Tight Stop Placement - Newser
Nuvectis Pharma Inc. Stock Chart Analysis: Bullish or Bearish Pattern FormingTrend Reversal Watch with Entry Signals - Newser
Q3 EPS Estimates for Nuvectis Pharma Reduced by Roth Capital - Defense World
Will a bounce in Nuvectis Pharma Inc. offer an exitFree Consistent Profit Pattern Recognition Tools - Newser
Nuvectis Pharma’s Strategic Focus on NXP900 and Positive Outlook Amidst Promising Developments - TipRanks
Nuvectis Pharma Reports Q2 2025 Financial Results and Progress - TipRanks
Exit strategy if you’re trapped in Nuvectis Pharma Inc.Stable Profit Zone and Loss Control Analysis - Newser
Nuvectis Pharma reports Q2 EPS (30c) vs. (26c) last year - TipRanks
Nuvectis Pharma: A Biotech Gem in the Shadows of GAAP Losses - AInvest
Nuvectis Pharma, Inc. Reports Second Quarter 2025 Financial Results and Business Highlights - The Manila Times
Nuvectis Reports Clinical Trial Success: NXP900 Cancer Drug Advances as Cash Position Strengthens to $39M - Stock Titan
0.11%
1.56%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):